Get the Stockscreener App
59.65
1.69%
0.99
After Hours:
59.65
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Bio Techne Corp stock is traded at $59.65, with a volume of 1.54M.
It is up +1.69% in the last 24 hours and up +16.37% over the past month.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
See More
Previous Close:
$58.66
Open:
$59.35
24h Volume:
1.54M
Relative Volume:
0.65
Market Cap:
$9.29B
Revenue:
$1.17B
Net Income/Loss:
$150.71M
P/E Ratio:
63.46
EPS:
0.94
Net Cash Flow:
$245.03M
1W Performance:
-3.67%
1M Performance:
+16.37%
6M Performance:
+17.61%
1Y Performance:
-18.69%
1-Day Range:
$58.23
$59.88
1-Week Range:
$57.85
$63.28
52-Week Range:
$46.01
$80.80
Bio Techne Corp Stock (TECH) Company Profile
Name
Bio Techne Corp
Sector
Industry
Phone
(612) 379-8854
Address
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
59.65 | 9.13B | 1.17B | 150.71M | 245.03M | 0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-21-25 | Upgrade | Citigroup | Neutral → Buy |
| Jul-22-25 | Resumed | Stephens | Overweight |
| Jul-09-25 | Initiated | TD Cowen | Buy |
| May-30-25 | Initiated | Wells Fargo | Overweight |
| Apr-09-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Mar-18-25 | Initiated | Evercore ISI | Outperform |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-08-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-02-24 | Downgrade | Stifel | Buy → Hold |
| Dec-07-23 | Initiated | UBS | Buy |
| Aug-28-23 | Initiated | William Blair | Outperform |
| Jan-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Sep-15-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-08-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-23-21 | Upgrade | Stifel | Hold → Buy |
| Jan-25-21 | Reiterated | The Benchmark Company | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Jul-15-20 | Downgrade | Stephens | Overweight → Equal-Weight |
| May-27-20 | Downgrade | Stifel | Buy → Hold |
| May-14-20 | Initiated | The Benchmark Company | Buy |
| Jan-08-20 | Resumed | Stephens | Overweight |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-02-19 | Upgrade | Janney | Neutral → Buy |
| Jan-14-19 | Upgrade | Stephens | Equal-Weight → Overweight |
| Oct-31-18 | Downgrade | Craig Hallum | Buy → Hold |
| Oct-17-18 | Initiated | Goldman | Neutral |
| Jun-15-18 | Initiated | Argus | Buy |
| Jul-13-17 | Initiated | Wells Fargo | Market Perform |
| Feb-09-17 | Initiated | Citigroup | Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Jan-21-15 | Reiterated | Robert W. Baird | Outperform |
| Sep-20-13 | Upgrade | Robert W. Baird | Neutral → Outperform |
View All
Bio Techne Corp Stock (TECH) Latest News
Smart tools for monitoring Bio Techne Corporation’s price actionMarket Movement Recap & Community Supported Trade Ideas - newser.com
Is Bio Techne Corporation stock a contrarian buy2025 AllTime Highs & Free Daily Entry Point Trade Alerts - newser.com
KLP Kapitalforvaltning AS Decreases Stake in Bio-Techne Corp $TECH - MarketBeat
Statistical indicators supporting Bio Techne Corporation’s strengthJuly 2025 Volume & Real-Time Stock Price Movement Reports - newser.com
Bio-Techne Corp. Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
Legal Advantage Investments Inc. Acquires 5,000 Shares of Bio-Techne Corp $TECH - MarketBeat
ConMed adds Bio-Techne CEO to board of directors - Central New York Business Journal
Bio-Techne (TECH): Valuation Spotlight Following Expanded Oxford Nanopore Partnership and Growth Strategy Realignment - Yahoo Finance
Visual analytics tools that track Bio Techne Corporation performance2025 Trade Ideas & Scalable Portfolio Growth Ideas - newser.com
Bio Techne Corporation stock daily chart insightsEarnings Growth Report & Smart Investment Allocation Insights - newser.com
Can Bio Techne Corporation recover in the next quarterWeekly Stock Summary & Verified Momentum Stock Alerts - newser.com
Will Bio Techne Corporation stock deliver shareholder valueJuly 2025 Momentum & Technical Pattern Based Signals - newser.com
Bio-Techne and Oxford Nanopore Technologies Expand Agreement to Accelerate Development of Genetics Portfolio Through 2032 - Investing News Network
Bio-Techne (TECH) Expands Partnership with Oxford Nanopore Technologies - GuruFocus
Bio-techne expands genetic testing collaboration with Oxford Nanopore - Investing.com
Bio-techne expands genetic testing collaboration with Oxford Nanopore By Investing.com - Investing.com South Africa
Is Bio Techne Corporation (TE1) stock resilient in recession scenariosTrade Entry Report & Reliable Price Action Trade Plans - newser.com
Should You Continue to Hold Bio-Techne Stock in Your Portfolio? - sharewise.com
Citi Sticks to Their Buy Rating for Bio-Techne (TECH) - The Globe and Mail
Bio-Techne (TECH) Receives a Buy from Evercore ISI - The Globe and Mail
Evercore ISI Group Raises Bio-Techne (TECH) Price Target to $72 | TECH Stock News - GuruFocus
Bio-Techne Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Citi Maintains Bio-Techne(TECH.US) With Buy Rating, Maintains Target Price $70 - 富途牛牛
How Bio Techne Corporation stock performs in rate cut cyclesTrade Risk Assessment & Reliable Breakout Stock Forecasts - newser.com
20,000 Shares in Bio-Techne Corp $TECH Purchased by Hunter Perkins Capital Management LLC - MarketBeat
Will Bio-Techne's (TECH) Latest Spatial Biology Tools Reshape Its Edge in Translational Research? - simplywall.st
Bio-Techne (TECH) Surges Over 21% as Healthcare Stocks Rally - GuruFocus
Bio Techne Corporation stock volume spike explained2025 Trade Ideas & Daily Profit Focused Stock Screening - newser.com
Bio-Techne Corp. Hits Day High with 10.2% Surge in Strong Intraday Performance - Markets Mojo
Bio-Techne (TECH): Assessing the Valuation as Shares Continue Their Recent Upward Momentum - simplywall.st
Why Bio Techne Corporation (TE1) stock trades below fair value2025 Pullback Review & AI Forecasted Entry/Exit Points - newser.com
Can Bio Techne Corporation (TE1) stock beat analyst consensusWeekly Market Report & Low Risk Entry Point Guides - newser.com
Centene, QuidelOrtho, iRhythm, and Bio-Techne Shares Skyrocket, What You Need To Know - The Globe and Mail
Could Spatial Biology Advances Shape Bio-Techne's (TECH) Long-Term Position in Precision Medicine? - Yahoo Finance
Bio-Techne Corp. stock outperforms competitors on strong trading day - MSN
Park Avenue Securities LLC Acquires Shares of 5,244 Bio-Techne Corp $TECH - MarketBeat
The Best Biotech Stocks to Buy - Morningstar
Bruker, Agilent, Revvity, Avantor, and Bio-Techne Shares Are Soaring, What You Need To Know - Yahoo Finance
Bio-Techne (TECH) Shares Skyrocket, What You Need To Know - Yahoo Finance
What analysts say about Bio Techne Corporation TE1 stockIPO Market Watch & Free Discover Dynamic Stocks - earlytimes.in
Bio-Techne (NASDAQ:TECH) Trading Up 4.7%What's Next? - MarketBeat
Is Bio Techne Corporation (TE1) stock positioned for secular growthDollar Strength & Real-Time Buy Signal Alerts - newser.com
Bio-Techne Stock Climbs on Advances in Spatial Biology Solutions - The Globe and Mail
Bio-Techne Corp $TECH Shares Bought by Fort Washington Investment Advisors Inc. OH - MarketBeat
Bio Techne Corp Stock (TECH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bio Techne Corp Stock (TECH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nusse Roeland | Director |
Aug 25 '25 |
Sale |
56.36 |
17,040 |
960,388 |
44,559 |
| BAUMGARTNER ROBERT V | Director |
Aug 25 '25 |
Option Exercise |
21.84 |
17,040 |
372,154 |
61,903 |
| BAUMGARTNER ROBERT V | Director |
Aug 25 '25 |
Sale |
56.21 |
17,040 |
957,818 |
44,863 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):